论文部分内容阅读
在血小板中合成的血栓素A_2(TXA_2)具有强力的血小板凝集作用和血管收缩作用。由于冠血管壁的硬化性病变使血小板激活,在冠循环中释放出来的TXA_2可诱发微血栓或痉挛,因而促进冠血流进一步减低和血小板凝集,继之发生心肌缺血;另一方面,在血管壁产生的前列环素(Prostacyclin,PGE_2)由于其对血小板凝集的抑制作用和血管扩张作用可拮抗TXA_2,故可望应用于缺血性心脏病的治疗。
Thromboxane A 2 (TXA 2), synthesized in platelets, has potent platelet aggregation and vasoconstriction effects. TXA 2 released in the coronary circulation induces microthrombosis or spasm due to sclerotic lesions of the coronary vessel wall, thereby promoting further reduction of coronary blood flow and platelet aggregation followed by myocardial ischemia; on the other hand, Prostacyclin (PGE 2) produced by the vascular wall is expected to be used in the treatment of ischemic heart disease due to its inhibitory effect on platelet aggregation and vasodilator antagonism of TXA_2.